Corti Marcelo, Villafañe Maria Florencia, Solari Ruben, De Carolis Luis, Cangelosi Diana, Santoro Jose, Schtirbu Ricardo, Lewi Daniel, Bistmans Alicia, Narbaitz Marina, Baré Patricia
Division B, Infectious Diseases F. J. Muñiz Hospital, Puán 381 2º C 1406 CQG, Buenos Aires, Argentina.
J Gastrointest Cancer. 2011 Sep;42(3):143-8. doi: 10.1007/s12029-010-9173-9.
Extranodal non-Hodgkin lymphoma (NHL) were commonly described in AIDS patients and are related with an atypical morphology and aggressive clinical course.
In this single institutional study we evaluated the epidemiological, clinical, immunological, virological, histopathological and the outcome of eleven HIV/AIDS patients with oral cavity lymphomas (OCL).
Nine were males and seven intravenous drug abusers. The median of age was 33 years and the median of CD4 T cell counts at the time of diagnosis was 97 cell/µL. The majority of tumors presented as large and ulcerated masses involving the gingiva, the palate and the jaw. Six of these tumors were diffuse large B-cell lymphomas (DLBCL); three were Burkitt's lymphomas and the final case was a plasmablastic lymphoma. An association with Epstein-Barr virus (EBV) was found in three of the ten tested cases by in situ hybridization (EBER 1 and 2 probes) and immunohistochemistry (LMP-1). Human herpes virus-8 (HHV-8) was detected by polymerase chain reaction (PCR) in only one neoplasm. Six patients died without specific treatment; four received chemotherapy and highly active antiretroviral therapy (HAART) and three of them presented a prolonged survival.
Combination of HAART and chemotherapy should modify the poor prognosis of AIDS patients with OCL.
结外非霍奇金淋巴瘤(NHL)常见于艾滋病患者,其形态不典型,临床病程侵袭性强。
在这项单中心研究中,我们评估了11例患有口腔淋巴瘤(OCL)的HIV/AIDS患者的流行病学、临床、免疫学、病毒学、组织病理学及预后情况。
9例为男性,7例为静脉吸毒者。年龄中位数为33岁,诊断时CD4 T细胞计数中位数为97个/微升。大多数肿瘤表现为累及牙龈、腭部和颌骨的巨大溃疡肿块。其中6例肿瘤为弥漫性大B细胞淋巴瘤(DLBCL);3例为伯基特淋巴瘤,最后1例为浆母细胞淋巴瘤。通过原位杂交(EBER 1和2探针)和免疫组化(LMP-1)在10例检测病例中的3例发现与爱泼斯坦-巴尔病毒(EBV)有关。仅在1例肿瘤中通过聚合酶链反应(PCR)检测到人疱疹病毒8型(HHV-8)。6例患者未接受特殊治疗死亡;4例接受了化疗和高效抗逆转录病毒治疗(HAART),其中3例生存期延长。
HAART与化疗联合应用应能改善患有OCL的艾滋病患者的不良预后。